

Datametrex AI Limited

Condensed Interim Consolidated Financial Statements
September 30, 2025

(Unaudited)

(Canadian dollars, except as otherwise noted)

Notice to Reader

The accompanying unaudited condensed consolidated interim financial statements of the Company have been prepared by and are the responsibility of the Company's management. The Company's independent auditor has not performed a review of these financial statements in accordance with standards established by the Chartered Professional Accountants of Canada for a review of interim financial statements by an entity's auditor.

Datametrex AI Limited

Condensed Interim Consolidated Statements of Financial Position

As of September 30, 2025 and March 31, 2025

(Canadian dollars)

	September 30, 2025	March 31, 2025
	\$	\$
Assets		(Audited)
Current assets		
Cash	253,444	368,107
Trade and loan receivables (notes 4 and 12)	2,750,094	2,565,875
Marketable securities (note 10)	58,999	58,999
Prepaid expenses and other assets	605,024	208,015
Total current assets	3,667,561	3,200,996
Right-of-use asset (note 8)	3,008,387	1,069,900
Property and equipment (note 5)	685,994	716,127
Goodwill (notes 6 and 14)	1,115,104	-
Total assets	8,477,046	4,987,023
Liabilities and shareholders' equity		
Current liabilities		
Accounts payable and accrued liabilities (note 12)	2,090,313	1,328,574
Income taxes payable	1,166,014	1,166,014
Current portion of lease liability (note 8)	458,453	116,403
Loans payable (notes 9 and 12)	1,512,256	682,912
Total current liabilities	5,227,036	3,293,903
Long-term lease liability (note 8)	2,819,370	1,036,719
Total liabilities	8,046,406	4,330,622
Shareholders' equity		
Share capital (note 11)	60,504,127	59,184,127
Reserves (note 11)	9,649,138	9,649,138
Foreign currency translation reserve	(72,106)	(77,288)
Deficit	(69,650,519)	(68,099,576)
Total shareholders' equity	430,640	656,401
Total liabilities and shareholders' equity	8,477,046	4,987,023
Description of business and organization (note 1)		
Contingency (note 15)		

Signed "Paul Haber" Director

Signed "Youngcho Lee" Director

The accompanying notes are an integral part of the condensed interim consolidated financial statements.

Datametrex AI Limited

Condensed Interim Consolidated Statements of Loss and Comprehensive Loss

For the three and six months ended September 30, 2025 and 2024

(Canadian dollars, except share and per share amounts)

	Three months ended September 30, 2025 \$	Three months ended September 30, 2024 \$	Six months ended September 30, 2025 \$	Six months ended September 30, 2024 \$
Revenue				
AI and Technology	442,962	257,343	866,539	738,841
Health Security	654,729	1,861,240	1,346,763	2,578,433
	1,097,691	2,118,583	2,213,302	3,317,274
Direct costs	(781,998)	(544,710)	(1,315,015)	(1,177,222)
Gross profit	315,693	1,573,873	898,287	2,140,052
Expenses				
Salaries, benefits and consulting fees	398,730	342,311	747,235	643,630
Office and general	240,591	341,578	496,213	561,503
Professional fees	92,755	805,605	599,468	1,214,186
Other operating expenses	11,881	34,751	91,954	78,197
Share-based compensation (note 11)	-	173,946	-	346,615
Depreciation and amortization (notes 5 and 8)	66,337	366,503	280,722	715,008
	810,294	2,064,694	2,215,592	3,559,139
Loss before undernoted items	(494,601)	(490,821)	(1,317,305)	(1,419,087)
Unrealized gain (loss) on marketable securities	-	146,500	-	(289,249)
Gain on sale of marketable securities	-	-	-	55,527
Interest and accretion	(155,538)	(23,890)	(213,784)	(46,539)
Interest and other income	363	66,146	467	71,752
Foreign exchange gain (loss)	-	13	-	13
Write off of accounts payable	-	18,320	-	18,320
Net loss from continuing operations	(649,776)	(283,732)	(1,530,622)	(1,609,263)
Discontinued operations				
Net income (loss) from discontinued operations, net of tax	(1,981)	(48,520)	(20,321)	(21,329)
Net loss	(651,757)	(332,252)	(1,550,943)	(1,630,592)
Other comprehensive loss				
Foreign exchange translation adjustment	(8,003)	83,269	5,182	70,869
Comprehensive loss	(659,760)	(248,983)	(1,545,761)	(1,559,723)
Weighted average number of common shares – basic and diluted	32,386,006	19,393,183	28,418,793	17,760,053
Basic and diluted loss per share from continuing operations	(0.02)	(0.01)	(0.05)	(0.09)
Basic and diluted loss per share from discontinued operations	(0.00)	(0.01)	(0.00)	(0.09)

The accompanying notes are an integral part of the condensed interim consolidated financial statements.

Datametrex AI Limited

Condensed Interim Consolidated Statements of Changes in Shareholders' Equity

For the six months ended September 30, 2025 and 2024

(Canadian dollars, except for number of shares)

	<u>Common Shares</u>		Reserves	Foreign currency translation reserve	Deficit	Total
	Number	Amount \$				
Balance – March 31, 2024	15,262,823	56,846,173	8,993,180	(54,562)	(64,780,328)	1,004,463
Net loss for the period	-	-	-	-	(1,630,592)	(1,630,592)
Shares issued for asset acquisition	2,333,333	1,050,000	-	-	-	1,050,000
Share issued for cash	2,536,516	1,521,909	-	-	-	1,521,909
Share-based compensation	-	-	346,615	-	-	346,615
Foreign exchange translation adjustment	-	-	-	70,869	-	70,869
Balance – September 30, 2024	20,132,672	59,418,082	9,339,795	16,307	(66,410,920)	2,363,264
Balance – March 31, 2025	21,386,006	59,184,127	9,649,138	(77,288)	(68,099,576)	656,401
Net loss for the period	-	-	-	-	(1,550,943)	(1,550,943)
Shares issued for business acquisition	11,000,000	1,320,000	-	-	-	1,320,000
Foreign exchange translation adjustment	-	-	-	5,182	-	5,182
Balance – September 30, 2025	32,386,006	60,504,127	9,649,138	(72,106)	(69,650,519)	430,640

The accompanying notes are an integral part of the condensed interim consolidated financial statements.

Datametrex AI Limited

Condensed Interim Consolidated Statements of Cash Flows

For the six months ended September 30, 2025 and 2024

(Canadian dollars)

	Six months ended September 30, 2025 \$	Six months ended September 30, 2024 \$
Cash flows used in operating activities		
Net loss for the period from continuing operations	(1,530,622)	(1,609,263)
Adjustments to reconcile net loss to operating cash flows		
Depreciation of property and equipment	128,756	246,553
Amortization of intangible assets	-	126,400
Amortization of right-of use asset	151,966	349,619
Accretion on lease liability	126,494	34,178
Accretion on long-term debt	86,558	12,550
Gain on sale of marketable securities	-	(55,527)
Share-based payments	-	289,249
Unrealized loss on marketable securities	-	346,615
Net change in operating assets and liabilities (note 7)	217,870	(1,024,194)
Cash used in operating activities – continuing operations	(818,978)	(1,283,820)
Cash provided by operating activities – discontinued operations	(18,000)	(21,329)
	<u>(836,978)</u>	<u>(1,305,149)</u>
Cash flows provided by investing activities		
Purchase of property and equipment	-	(344,911)
Proceeds from the sale of marketable securities	-	236,577
Cash obtained from Arbutus Health acquisition	18,548	150,000
	<u>18,548</u>	<u>41,666</u>
Cash flows provided by financing activities		
Repayments of lease liability	(122,485)	(409,988)
Repayments of loan payable	(40,000)	-
Proceeds from loan payable	861,134	29,500
Proceeds from private placement	-	1,521,909
Cash provided by financing activities	698,649	1,414,221
Effect of exchange rate changes on cash and cash equivalents	5,118	70,777
Decrease in cash and cash equivalents	(114,663)	(51,285)
Cash, beginning of period	368,107	341,242
Cash, end of period	<u>253,444</u>	<u>289,957</u>
Supplementary information		
Interest paid	-	-
Income taxes paid	-	-

The accompanying notes are an integral part of the condensed interim consolidated financial statements.

Datametrex AI Limited

Notes to Condensed Interim Consolidated Financial Statements

For the six months ended September 30, 2025 and 2024

(Canadian dollars)

1 Description of business and organization

Datametrex AI Limited (the “Company”) is a technology company focused on collecting, analyzing and presenting structured and unstructured data using machine learning and artificial intelligence. The Company also started health care businesses including COVID-19 related services, concierge medical services and telemedicine services.

The Company is a publicly traded corporation, incorporated in the province of Ontario and its head office and principal place of business is located at 2300 Yonge Street, Suite 2802, Toronto, Ontario, M4P 1E4, Canada. The Company’s common shares are listed on the TSX Venture Exchange (“TSXV”) under the trading symbol “DM” and on the Frankfurt Stock Exchange under the trading symbol “D4G”.

During the six months ended September 30, 2025, the Company reported a net loss of \$1,550,943 (2024 – \$1,630,592) and, as of that date, the Company had accumulated deficit of \$69,650,519 (March 31, 2025 - \$68,099,576) and a working capital deficit of \$1,559,475 (March 31, 2025 – deficit of \$92,907). The Company’s continuing operations as intended are dependent upon its the ability to raise additional funds, investor sentiment and financial market conditions. The Company continues to seek capital through various means including the issuance of equity and/or debt. Should the Company be unable to secure additional financing, the Company may be unable to discharge its net liabilities. These uncertainties may cast significant doubt upon the Company’s ability to continue as a going concern. In order to continue as a going concern and to meet its corporate objectives, the Company will require additional financing through debt or equity issuances or other available means. Although the Company has been successful in the past in obtaining financing, there is no assurance that it will be able to obtain adequate financing in the future or that such financing will be on terms advantageous to the Company.

2 Material accounting policy information

Basis of presentation and statement of compliance

These condensed consolidated interim financial statements have been prepared in accordance International Accounting Standards (“IAS”) 34 – Interim Financial Reporting of International Financial Reporting Standards (“IFRS”), as issued by the International Accounting Standards Board (“IASB”). Accordingly, certain information and footnote disclosure normally included in annual financial statements have been omitted or condensed.

The preparation of financial statements in accordance with IAS 34 requires the use of certain critical accounting estimates. It also requires management to exercise judgment in applying the Company’s accounting policies. The areas involving a higher degree of judgment or complexity, or areas where assumptions and estimates are significant to the financial statements have been set out in note 2 to the Company’s consolidated financial statements for the year ended March 31, 2025. These interim financial statements should be read in conjunction with the Company’s consolidated financial statements for the year ended March 31, 2025. The accounting policies have been applied consistently in these interim financial statements, unless otherwise indicated.

These condensed consolidated interim financial statements were approved and authorized for issuance by the Company’s Board of Directors on November 25, 2025. The consolidated financial statements are presented in Canadian dollars which is also the Company’s functional currency.

Datametrex AI Limited

Notes to Condensed Interim Consolidated Financial Statements

For the six months ended September 30, 2025 and 2024

(Canadian dollars)

Basis of consolidation

The condensed interim consolidated financial statements include the accounts of all entities controlled by the Company, which are referred to as subsidiaries, and references to the Company include references to such subsidiaries. The financial statements of the subsidiaries are included in these consolidated financial statements from the date on which control commences until the date on which control ceases.

The Company's wholly owned operating subsidiaries include:

Name of the entity	Jurisdiction of incorporation	Functional currency	Principal activity
Datametrex Limited	Canada	Canadian Dollar	Inactive
9172-8766 Quebec Inc. ("Nexalogy")	Canada	Canadian Dollar	AI and Technology
Datametrex Korea Limited ("Datametrex Korea")	Korea	Korean Won	AI and Technology
Medi-Call Inc. ("Medi-Call")	Canada	Canadian Dollar	Inactive
Datametrex Electric Vehicle Solutions Inc. ("EVS") ⁽¹⁾	Canada	Canadian Dollar	AI and Technology
Imagine Health Medical Clinics Ltd. ("IHMed") ⁽²⁾	Canada	Canadian Dollar	Health Care
Imagine Health Pharmacies & Research Ltd. ("IHPharma") ⁽²⁾⁽³⁾	Canada	Canadian Dollar	Health Care
Imagine Health Physio Ltd. ("IHPhysio") ⁽²⁾⁽³⁾	Canada	Canadian Dollar	Health Care
Arbutus Health and Wellness Inc. ("Arbutus Health")	Canada	Canadian Dollar	Health Care

(1) Deconsolidated as of December 7, 2023, being the date of disposition.

(2) Consolidated as of May 1, 2023, being the date of acquisition.

(3) Classified as discontinued operation as at March 31, 2025.

The Company's consolidated financial statements are presented in Canadian Dollar.

Intercompany balances and transactions are eliminated upon consolidation and preparation of these consolidated financial statements.

Discontinued Operations

Discontinued operations are presented in the consolidated statements of operations as a separate line.

Critical Accounting Estimates and Judgments

The preparation of these consolidated financial statements in conformity with IFRS requires management to make estimates and judgments that affect the applications of accounting policies regarding certain types of assets, liabilities, revenues, and expenses in the preparation of these consolidated financial statements. Estimates and judgments are reviewed on an ongoing basis. Revisions to accounting estimates are recognized in the year in which the estimates are revised and in any future years affected. These estimates and judgments are based on management's historical experience, and its best knowledge of current events or conditions and activities that the Company may undertake in the future. Actual results could differ materially from these estimates.

Datametrex AI Limited

Notes to Condensed Interim Consolidated Financial Statements

For the six months ended September 30, 2025 and 2024

(Canadian dollars)

Judgments

Information about critical judgments in applying accounting policies that have the most significant risk of causing material adjustment to the amounts reported in these consolidated financial statements are discussed below:

a) **Business combinations, control and significant influence**

The Company uses judgment in determining the entities that it controls and therefore, consolidates or has significant influence over and therefore accounts for on an equity basis. The Company controls an entity when the Company has existing rights that give it the current ability to direct the activities that significantly affect the entities' returns. The Company has significant influence when the Company has the power to participate in the financial and operating policy decisions of the investee, but does not control nor has joint control of that investee's policies.

b) **Intangible assets and goodwill**

Management is required to use judgment in determining the economic useful lives of identifiable intangible assets. Judgment is also required to determine the frequency with which these assets are to be tested for impairment. The Company uses judgment in determining the grouping of assets to identify its Cash Generating Units ("CGUs") for purposes of testing for impairment of intangible assets and goodwill. In testing for impairment, goodwill acquired in a business combination is allocated to the CGUs that are expected to benefit from the synergies of the business combination. In testing for impairment of intangibles with indefinite lives, these assets are allocated to the CGUs to which they relate.

c) **Income taxes**

In calculating current and deferred income taxes, the Company uses judgment when interpreting the tax rules where the Company operates. The Company also uses judgment in classifying transactions and assessing probable outcomes of claimed or accrued deductions, which considers expectations of future operating results, the timing and reversal of temporary differences and possible audits of income tax filings by tax authorities.

d) **Accounting for the business acquisitions**

The Company applies significant judgment to conclude whether an acquired set of activities and assets is a business. The acquisition of a business is accounted for as a business combination, under IFRS 3. If an acquired set of activities and assets does not meet the definition of a business, the transaction is accounted for as an asset acquisition. The Company also applied judgment in identifying the assets acquired and evaluating which IFRS standard the asset should be measured in.

Datametrex AI Limited

Notes to Condensed Interim Consolidated Financial Statements

For the six months ended September 30, 2025 and 2024

(Canadian dollars)

Estimates

The effect of a change in an accounting estimate is recognized prospectively by including it in profit or loss in the year of the change, if the change affects that year only, or in the year of the change and future years, if the changes affects both.

a) **Accrued liabilities, provisions and contingent consideration**

Certain estimates and assumptions that have a significant risk of causing material adjustments to the carrying amount of assets and liabilities within the next fiscal year include accrued liabilities, provisions and contingent consideration. These estimates are based on management's assumptions, based on current circumstances, that management believes are a reasonable basis upon which to estimate the future liabilities. Specifically for provisions, that the amount of the estimate is reliable and that management has determined that there is an expectation that future outflows of assets will be necessary to cover the provided for amounts.

b) **Fair value of intangible assets and goodwill**

With respect to intangible assets acquired and goodwill recognized in a business combination, and at subsequent assessment dates, the Company determines fair values using such estimates such as discounts rates, growth rates and terminal growth rates. These estimates take into account any material change to the assumptions that occur when reviewed annually by management.

3 Segment information

For the six months ended September 30, 2025 and the year ended March 31, 2025, the Company has two operating and reportable segments being: (1) AI and Technology; and (2) Health Care.

Management evaluates the performance of each segment based on its profitability.

	Health Care	AI and Technology	Consolidated totals
	\$	\$	\$
For the six months ended September 30, 2025			
Revenue	1,346,763	866,539	2,213,302
Direct costs	775,823	539,192	1,315,015
Gross profit	570,940	327,347	898,287
Interest expense	213,784	-	213,784
Depreciation	280,069	653	280,722
Segment (loss) income	(1,449,562)	(101,381)	(1,550,943)

For the six months ended September 30, 2024

Revenue	2,578,433	738,841	3,317,274
Direct costs	888,604	288,618	1,177,222
Gross profit	1,689,829	450,223	2,307,645
Interest expense	46,539	-	46,539
Depreciation	706,584	8,424	715,008
Segment (loss) income	(1,685,218)	54,626	(1,630,592)

Datametrex AI Limited

Notes to Condensed Interim Consolidated Financial Statements

For the six months ended September 30, 2025 and 2024

(Canadian dollars)

As at September 30, 2025

Segment total assets	7,482,792	994,254	8,477,046
Segment non-current assets	4,806,700	2,785	4,809,485
Segment liabilities	6,996,596	1,049,810	8,046,406

As at March 31, 2025

Segment total assets	2,805,991	2,181,032	4,987,023
Segment non-current assets	831,393	954,634	1,786,027
Segment liabilities	3,930,309	400,313	4,330,622

The Company operates in two geographic locations, being Canada and Korea. Geographical information is summarized as follows:

	Canada \$	Korea \$	Total \$
For the six months ended September 30, 2025			
Revenue from external customers	1,346,763	866,539	2,213,302
Non-current assets	4,806,700	2,785	4,809,485
	Canada \$	Korea \$	Total \$
For the six months ended September 30, 2024			
Revenue from external customers	2,578,433	738,841	3,317,274
Non-current assets	9,304,658	252,626	9,557,284

4 Trade and loan receivables

	September 30, 2025 \$	March 31, 2025 \$
Trade receivables	2,001,590	1,693,870
Sales taxes receivable	748,504	872,005
	<u>2,750,094</u>	<u>2,565,875</u>

Datametrex AI Limited

Notes to Condensed Interim Consolidated Financial Statements

For the six months ended September 30, 2025 and 2024

(Canadian dollars)

5 Property and equipment

	Computer equipment, software and machinery \$	Office equipment and furniture \$	Leasehold improvements \$	Total \$
Cost				
Balance at March 31, 2024	3,153,242	64,903	578,471	3,796,616
Additions	-	-	344,912	344,912
Disposition	(51,238)	-	-	(51,238)
Effect of foreign exchange	-	(519)	-	(519)
Balance at March 31, 2025	3,102,004	64,384	923,383	4,089,771
Additions	100,000	-	-	100,000
Effect of foreign exchange	51,236	353	-	51,589
Balance at September 30, 2025	3,253,240	64,737	923,383	4,241,360
Accumulated depreciation				
Balance at March 31, 2024	1,864,748	43,648	17,126	1,925,522
Depreciation	636,377	16,655	15,333	668,365
Disposition	(51,238)	-	-	(51,238)
Impairment	-	-	831,396	831,396
Effect of foreign exchange	-	(401)	-	(401)
Balance at March 31, 2025	2,449,887	59,902	863,855	3,373,644
Depreciation	125,910	1,764	2,523	130,197
Effect of foreign exchange	51,239	286	-	51,525
Balance at September 30, 2025	2,627,036	61,952	866,378	3,555,366
Carrying amounts				
Balance at March 31, 2025	652,117	4,482	59,528	716,127
Balance at September 30, 2025	626,204	2,785	57,005	685,994

Datametrex AI Limited

Notes to Condensed Interim Consolidated Financial Statements

For the six months ended September 30, 2025 and 2024

(Canadian dollars)

6 Goodwill and other intangible assets

	Goodwill \$	Trademark \$	Non- competition agreements and others \$	Patents and developed technologies \$	Customer relationships \$	Total intangibles \$
Cost						
Balance at March 31, 2024	4,444,997	400,000	14,840,342	17,191,576	2,102,000	34,533,918
Acquisition – Cereal Crunch	-	-	-	900,000	-	900,000
Balance at March 31, 2025	4,444,997	400,000	14,840,342	18,091,576	2,102,000	35,433,918
Acquisition – Arbutus Health	1,115,104	-	-	-	-	-
	5,560,101	400,000	14,840,342	18,091,576	2,102,000	35,433,918
Accumulated amortization and impairment losses						
Balance at March 31, 2024	2,972,348	400,000	14,587,175	17,191,576	1,401,639	33,580,390
Amortization	-	-	62,000	108,986	152,333	323,319
Impairment	1,472,649	-	191,167	791,014	548,028	1,530,209
Balance at March 31, 2025 and September 30, 2025	4,444,997	400,000	14,840,342	18,091,576	2,102,000	35,433,918
Carrying amounts						
Balance at March 31, 2025	-	-	-	-	-	-
Balance at September 30, 2025	1,115,104	-	-	-	-	-

Nexalogy

Trademarks and other intangibles include indefinite life trademarks in the amount of \$400,000 relating to the Nexalogy brand. The goodwill and indefinite life trademarks are both a result of the Nexalogy acquisition. During the fifteen months ended March 31, 2024, the Company halted Nexalogy operations and management decided to shift focus to other business ventures resulting in the Company completely writing down its trademarks, other intangibles and goodwill by recording an impairment loss of \$3,831,603.

Medi-Call

During the year ended December 31, 2022, the Company recorded an impairment loss of \$4,520,112 related to its developed technologies related to Medi-Call, due to Medi-Call falling short of the expected revenues and financial performance during the year. The impairment was determined using a value in use recoverable amount calculation, utilizing a 34.8% discount rate, which is consistent with the original valuation of the developed technology at the acquisition during the year ended December 31, 2021. During the fifteen months ended March 31, 2024, Medi-Call operation did not generate expected revenues and management decided to shift focus to other business ventures resulting in the Company completely writing down its developed technologies by recording an additional impairment loss of \$6,743,847.

Imagine Health

During the year ended March 31, 2025, the Company recorded an impairment loss of \$2,211,844 related to its customer relationships, brand and goodwill due to Imagine Health falling short of the expected financial performance during the year. The impairment was determined using a value in use recoverable amount calculation, utilizing a 30% discount rate, which is consistent with the original valuation at the acquisition (note 14).

Datametrex AI Limited

Notes to Condensed Interim Consolidated Financial Statements

For the six months ended September 30, 2025 and 2024

(Canadian dollars)

Cereal Crunch Mobile Game

On May 9, 2024, the Company completed the arm's length acquisition of the mobile blockchain game Cereal Crunch. The Company acquired all assets related to Cereal Crunch, including the game software, intellectual property, user databases, and \$150,000 in cash. For consideration, the Company issued 2,333,333 common shares valued at \$1,050,000 (note 11). Cereal Crunch launched on Google Play in August 2024. During the year ended March 31, 2025, the Company halted the Cereal Crunch mobile game and management decided to shift focus to other business ventures resulting in the Company completely writing down its intangibles assets by recording an impairment loss of \$791,014.

Arbutus Health

On June 5, 2025, the Company completed the acquisition of Arbutus Health, resulting in a goodwill of \$1,115,104 (note 14).

Impairment

During the year ended March 31, 2025, the Company discontinued the operations of IHPharma, IHPhysio and Cereal Crunch. The recoverable amount of these operations using value in use was determined to be \$Nil. As a result, the Company fully impaired the intangibles and goodwill associated with these operations in the total amount of \$1,530,209.

7 Net change in operating assets and liabilities

	Six months ended September 30, 2025 \$	Six months ended September 30, 2024 \$
Cash flows provided by (used in)		
Trade and loan receivables	(177,016)	(1,463,889)
Inventory	-	(174,070)
Prepaid expenses and other assets	(354,785)	(2,257)
Due to related parties	33,625	-
Accounts payable and accrued liabilities and provisions	716,046	616,022
	<u>217,870</u>	<u>1,024,194</u>

8 Right-of-use asset and lease liability

During the year ended December 31, 2021, the Company entered into a new lease contract for its office on Yonge Street in Toronto. The lease expired in September 2024. In July 2024, The Company entered into an amendment related to modifying the monthly lease cost and extending the lease term to April 2026.

During the twelve months ended December 31, 2022, the Company entered into a new lease contract for its office on Arbutus Street in Vancouver. The lease expires in August 2032. In January 2025, the lease agreement was terminated resulting in the Company recognizing a gain on lease termination of \$75,357 during the year ended March 31, 2025.

During the fifteen months ended March 31, 2024, the Company acquired two leases for its premise on 97 Street in Edmonton expiring in December 2035 and one lease for 6th Avenue SE in Calgary expiring in December 2024. In October 2024, the Company entered into an amendment on one Edmonton lease related to modifying the monthly lease cost and changing the lease term to June 2034. During the year ended March 31, 2025, the Company terminated the other lease related to 97 Street in Edmonton resulting in the Company recognizing a gain on lease termination of \$10,472.

Datametrex AI Limited

Notes to Condensed Interim Consolidated Financial Statements

For the six months ended September 30, 2025 and 2024

(Canadian dollars)

Right-of-use asset

	\$
Balance at March 31, 2024	4,990,729
Lease amendment	(216,832)
Amortization charge for the year	(595,228)
Lease termination	(3,108,769)
Balance at March 31, 2025	1,069,900
Acquisition of Arbutus Health (note 14)	2,090,453
Amortization charge for the year	(151,966)
Balance at September 30, 2025	3,008,387

Lease liability

	\$
Balance at March 31, 2024	5,195,256
Lease amendment	(216,832)
Accretion on lease liability	229,288
Lease payments	(688,028)
Lease termination	(3,366,562)
Balance at March 31, 2025	1,153,122
Acquisition of Arbutus Health (note 14)	2,120,692
Accretion on lease liability	126,494
Lease payments	(122,485)
Balance at September 30, 2025	3,277,823
Classified as current	458,453
Classified as non-current	2,819,370

When measuring the lease liability, the Company discounted lease payments using its incremental borrowing rate of 3.45% for lease agreements entered before 2023 and using its incremental borrowing rate of 9.95% to value the office lease entered during the year.

During the year ended March 31, 2025, rent expense related to an office premises lease, which was exempt from lease accounting due to its short-term nature, was \$54,611 (2024 - \$7,543). The rent expense associated with this lease is included within office and general in profit or loss.

Datametrex AI Limited

Notes to Condensed Interim Consolidated Financial Statements

For the six months ended September 30, 2025 and 2024

(Canadian dollars)

9 Loans Payable

	September 30, 2025	March 31, 2025
	\$	\$
Related parties, unsecured, non-interest bearing and due on demand (note 12)	184,647	15,800
Third party loan, unsecured, 18% interest per annum and due on demand. During the six months ended September 30, 2025, the Company accrued interest of \$58,396 (2024 - \$Nil).	1,016,642	341,496
Third party loan, unsecured and 20% interest per annum. The principal amounts are due all due within 12 months. During the six months ended September 30, 2025, the Company accrued interest of \$28,162 (2024 - \$Nil).	279,992	196,330
Third party loans, unsecured, non-interest bearing and due on demand	30,975	129,286
	<u>1,512,256</u>	<u>682,912</u>
Less: Current portion of long-term debt	<u>(1,512,256)</u>	<u>(682,912)</u>
	<u>-</u>	<u>-</u>

10 Marketable Securities

The continuity of marketable securities for the six months ended September 30, 2025 and the year ended March 31, 2025 is as follows:

	Justera Health Ltd.	New World Solutions Inc.	Total
	\$	\$	\$
Balance, March 31, 2024	117,998	675,000	792,998
Disposition	-	(543,150)	(543,150)
Fair value adjustment for the year	(58,999)	(131,850)	(190,849)
Balance, March 31, 2025 and September 30, 2025	<u>58,999</u>	<u>-</u>	<u>58,999</u>

At September 30, 2025, the Company had 11,799,800 common shares of Justera Health Ltd. valued at \$0.005 per share, and 2,930,000 common shares of New World Solutions Inc. valued at \$Nil per share.

11 Share capital and reserves

a) Common shares

The Company is authorized to issue an unlimited number of common shares with no par value.

On February 6, 2025, the Company consolidated its common shares on a 30 old shares into 1 new share basis. Unless otherwise noted, all figures have been retrospectively adjusted in these consolidated financial statements to reflect the share consolidation.

Datametrex AI Limited

Notes to Condensed Interim Consolidated Financial Statements

For the six months ended September 30, 2025 and 2024

(Canadian dollars)

For the six months ended September 30, 2025:

On June 5, 2025, the Company issued 11,000,000 common shares valued at \$1,320,000 to acquire Arbutus Health.

For the six months ended September 30, 2024:

On May 28, 2024, the Company issued 2,333,333 common shares valued at \$1,050,000 to acquire assets related to Cereal Crunch (note 7).

On July 5, 2024, the Company closed the first tranche of its non-brokered private placement of 1,075,833 units of the Company at a price of \$0.60 per unit for aggregate gross proceeds of \$645,500. Each Unit consists of one common share of the Company ("Share") and one common share purchase warrant ("Warrant"). Each Warrant entitles the holder to acquire one additional Share of the Company at a price of \$1.50 per Share for a period of two years from the date of issuance. The fair value of the Warrants was \$322,750 using the residual method.

On July 30, 2024, the Company closed the second tranche of its non-brokered private placement of 519,016 units of the Company at a price of \$0.60 per unit for aggregate gross proceeds of \$311,409. Each Unit consists of one common share of the Company and one common share purchase warrant. Each Warrant entitles the holder to acquire one additional Share of the Company at a price of \$1.50 per Share for a period of two years from the date of issuance. The fair value of the Warrants was \$155,705 using the residual method.

On August 19, 2024, the Company closed the final tranche of its non-brokered private placement of 941,667 units of the Company at a price of \$0.60 per unit for aggregate gross proceeds of \$565,000. Each Unit consists of one common share of the Company and one common share purchase warrant. Each Warrant entitles the holder to acquire one additional Share of the Company at a price of \$1.50 per Share for a period of two years from the date of issuance. The fair value of the Warrants was \$282,500 using the residual method.

b) **Share options**

The Company's omnibus equity incentive plan (the "Omnibus Plan") is a rolling plan which provides that the Board of Directors may from time to time, in its discretion, and in accordance with applicable policies of the TSX Venture Exchange ("TSXV"), grant options and restricted share units to acquire common shares to directors, officers and employees of the Company and its affiliates and to consultants, consultant companies and management company employees, provided that the common shares that may be reserved for issuance under the Omnibus Plan at any point in time will not be greater than 10% of the then issued and outstanding common shares. Options issued pursuant to the Omnibus Plan will have an exercise price determined by the Board of Directors provided that the exercise price will not be less than the "Discounted Market Price" as defined in the policies of the TSXV. The vesting of the Options is at the discretion of the Board, except in the case of an optionee performing investor relations activities, in which case the Omnibus Plan requires that options vest over a minimum of 12 months with no more than one quarter of such options vesting during any three month period.

Share options granted by the Company are recorded in "Reserves" in the consolidated statements of financial position as they vest. The following summarizes transactions involving share options issued by the Company:

	Number	Weighted average exercise price \$
Options outstanding at March 31, 2024	533,333	2.40
Options expired	(350,000)	2.40
Options outstanding at March 31, 2025	183,333	2.29

Datametrex AI Limited

Notes to Condensed Interim Consolidated Financial Statements

For the six months ended September 30, 2025 and 2024

(Canadian dollars)

Options expired	(183,333)	2.29
Options outstanding at September 30, 2025	-	-

c) **Warrants**

	Number	Weighted average exercise price \$
Warrants outstanding at March 31, 2024	1,672,000	1.50
Warrants issued	2,536,515	1.50
Warrants outstanding at March 31, 2025 and September 30, 2025	4,208,515	1.50

The weighted average remaining life of the warrants outstanding at September 30, 2025 is 0.66 years (March 31, 2025 – 1.16 years).

Datametrex AI Limited

Notes to Condensed Interim Consolidated Financial Statements

For the six months ended September 30, 2025 and 2024

(Canadian dollars)

d) Restricted share units

	Number
RSUs outstanding at March 31, 2024	1,153,334
RSUs exercised	(753,334)
RSUs cancelled	(400,000)
RSUs outstanding at March 31, 2025 and September 30, 2025	-

12 Related party transactions and balances

During the year, the Company incurred transactions with related parties, including companies controlled by its senior management and directors of the Company.

a) Accounts payable and accrued liabilities

Included in accounts payable and accrued liabilities at September 30, 2025 was \$268,450 (March 31, 2025 - \$148,265) due to officers, directors and/or companies with certain officers and directors in common of the Company.

During the year ended March 31, 2025, the Company recognized a write-off of accounts payable in the total amount of \$291,338 related to certain balances outstanding to a company controlled by a director of the Company and a company with certain officers and directors in common with the Company.

b) Trade receivables

Included in trade receivables at September 30, 2025 was \$1,388,038 (March 31, 2025 - \$1,488,038) due to a company with certain officers and directors in common of the Company.

During the year ended March 31, 2025, the Company recognized a write-off of trade receivables in the total amount of \$108,600 related to a balance outstanding to a company with certain officers and directors in common with the Company.

c) Loans payable

As at September 30, 2025, the Company has a loan payable to New World in an amount of \$15,800 (March 31, 2025 – \$15,800). The loan is unsecured, non-interest bearing and repayable on demand.

As at September 30, 2025, the Company has a loan payable to a company controlled by the CEO in the amount of \$168,847 (March 31, 2025 - \$Nil). The loan is unsecured, non-interest bearing and repayable on demand.

Datametrex AI Limited

Notes to Condensed Interim Consolidated Financial Statements

For the six months ended September 30, 2025 and 2024

(Canadian dollars)

d) Compensation of key management personnel

Related parties include key management personnel and others considered to have significant influence or control over the Company's operations. The Company considers key management personnel to include members of the Board of Directors and executive officers of the Company. Compensation to key management personnel is listed below:

	Six months ended September 30, 2025		Six months ended September 30, 2024	
	Amount \$	Options vested	Amount \$	Options vested
Short term compensation	240,000	-	-	-
Services included in direct costs	-	-	302,000	-
Share-based compensation	-	-	210,000	-
	240,000	-	265,427	-

13 Fair values of financial instruments

The Company is exposed to risks that arise from its use of financial instruments. This note describes the Company's objectives, policies and processes for managing those risks and the methods used to measure them. Further quantitative information in respect of these risks is presented below.

Management has overall responsibility for the determination of the Company's risk management objectives and policies and, whilst retaining ultimate responsibility for them, it has delegated the authority for designing and operating processes that ensure the effective implementation of the objectives and policies to the Company's finance function.

The overall objective of management is to set policies that seek to minimize risk as far as possible without unduly affecting the Company's competitiveness and flexibility. The Company has established risk management policies and procedures designed to reduce the potentially adverse effects of price volatility on operating results and distributions.

The Company's credit risk, liquidity risk and market risks are not materially different from those described in the Company's annual financial statements for the year ended 31 March 2025.

Fair values of financial instruments

IFRS 13 - *Fair value measurement*, requires disclosure of a three-level hierarchy ("FV hierarchy") that reflects the significance of the inputs used in making fair value measurements and disclosures. Fair values of assets and liabilities included in Level 1 are determined by reference to quoted prices in active markets for identical assets and liabilities. Assets and liabilities in Level 2 include those whose valuations are determined using inputs other than quoted prices for which all significant inputs are observable, either directly or indirectly. Level 3 valuations are those based on inputs that are unobservable and significant to the overall fair value measurement.

Cash and cash equivalents, trade and loan receivables, accounts payable and accrued liabilities and loans payable, have relatively short periods to maturity, and as such, the carrying values contained in the consolidated statements of financial position approximate their estimated fair value.

The Company's marketable securities are measured at fair value in the consolidated statement of financial position in accordance with level 1 of the fair value hierarchy.

Datametrex AI Limited

Notes to Condensed Interim Consolidated Financial Statements

For the six months ended September 30, 2025 and 2024

(Canadian dollars)

Capital management

The Company manages its capital to ensure that it will be able to continue as a going concern while maximizing the return to stakeholders through a suitable debt and equity balance appropriate for an entity of the Company's size and status. The Company's overall strategy remains unchanged from the prior year.

The capital structure of the Company consists of shareholders' equity, which totaled \$430,640 at September 30, 2025 (March 31, 2025 – \$656,401). The availability of new capital will depend on many factors including positive stock market conditions, results of operations thereby access to suitable debt products, and the experience of management. The Company is not subject to any external covenants on its capital.

14 Business acquisitions and disposals

Imagine Health

In November 2022, the Company entered into a Share Purchase Agreement under which the Company acquired all of the issued and outstanding shares of Imagine Health located in Calgary, Alberta and Edmonton, Alberta. The purchase price was as follows: cash payment of \$1,300,000 (paid), issuance of 166,667 common shares of the Company (issued) and the issuance of a secured vendor take-back note with a principal amount of \$800,000 payable in installments of 6, 12, and 18 months from the date of issuance (the "Note"). The Note was secured by the assets of Imagine Health. In addition, the Share Purchase Agreement includes a covenant to expand Imagine Health by way of working and growth capital contribution of up to \$1,000,000 to Imagine Health over a period of 12 months from the date of the acquisition.

In May 2023, the Company obtained control over the operations in both locations and, as such, the acquisition was considered completed. The acquisition was accounted for as a business combination consistent with IFRS 3, *Business Combination*. The preliminary purchase price allocation was as follows:

Purchase price	\$	2,434,731
Assets acquired and liabilities assumed		
Cash and cash equivalents	\$	110,605
Trade and other receivables		181,000
Inventory		158,151
Property and equipment		148,215
Right-of-use asset		1,977,754
Intangible assets		1,150,005
Accounts payable and other liabilities		(481,144)
Lease liability		(1,977,754)
Deferred income taxes		(304,750)
Net asset acquired	\$	962,082
Goodwill (note 6)		1,472,649
Total	\$	2,434,731

Datametrex AI Limited

Notes to Condensed Interim Consolidated Financial Statements

For the six months ended September 30, 2025 and 2024

(Canadian dollars)

Arbutus Health

In June 2025, the Company entered into a Share Exchange Agreement under which the Company acquired all of the issued and outstanding shares of Arbutus Health located in Vancouver, British Columbia. The purchase price was 11,000,000 common shares of the Company (issued) valued at \$0.12 per share.

The acquisition was accounted for as a business combination consistent with IFRS 3, *Business Combination*. The preliminary purchase price allocation was as follows:

Purchase price – preliminary	\$	1,320,000
Assets acquired and liabilities assumed – preliminary		
Cash and cash equivalents	\$	18,548
Trade and other receivables		11,850
Prepaid expenses		42,224
Right-of-use asset		2,090,453
Property and equipment		100,000
Intercompany loan forgiven upon acquisition		111,973
Accounts payable and other liabilities		(49,459)
Lease liability		(2,120,692)
Net asset acquired	\$	204,896
Goodwill (note 6)		1,115,104
Total	\$	1,320,000

15 Contingency

A former employee of the Company filed a claim for wrongful dismissal seeking damages aggregating \$135,000. The Company filed a defence and counterclaim denying the claim and counterclaiming for certain losses incurred by the Company. The Company intends to defend the claim vigorously and the outcome of the claim cannot be reasonably estimated at this time. Accordingly, no provision has been recorded for the year ended March 31, 2025 and for the six months ended September 30, 2025.

16 Discontinued operations

During the year ended March 31, 2025, the Company shut down the operations of IHPharma, IHPhysio and Cereal Crunch mobile game. Since there are no ongoing activities in these operations, the Company has classified them as discontinued operations. Certain amounts for the comparative period ended September 30, 2024 were reclassified to conform to current period's presentation.